Fillable Online impaactnetwork A Phase I/II Open-Label, Single-Arm Study to Evaluate the Fax Email Print - pdfFiller
Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC—a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier ...
Effect of Facial Cosmetic Acupuncture on Facial Elasticity: An Open-Label, Single-Arm Pilot Study – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open
![PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bd292c301c51a1f717d8f0c14788762c69120a87/4-Figure1-1.png "PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar")
PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar
An Open-Label, Single-Arm, Efficacy Study of Tranexamic Acid in Adolescents with Heavy Menstrual Bleeding - Journal of Pediatric and Adolescent Gynecology
An Open-label, Single-arm Study of CRYO2 for Debulking at the Site of Central Airway Obstruction or Stenosis | In Vivo
A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis - Gynecologic Oncology
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study - The Lancet Respiratory Medicine
The study was design as single-arm open-label trial consisting of a 14... | Download Scientific Diagram
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
3 month randomised double blind, placebo-controlled phase followed by a 24-month open-label, single-arm phase. The primary endpoint of the trial was to compare the efficiency (4) - Debra Ireland
New approaches to clinical trials: Adaptive designs - EUPATI Toolbox
Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment - Respiratory Medicine
A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus - Journal of Dermatological Science
CONSORT flowchart for A single-arm, open-label, phase 2 clinical trial... | Download Scientific Diagram
A Single Center Open Label Single Arm Study Evaluating Efficacy and Safety of Skin Adhesive EpinexusTM in Surgical Patients
Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study - Clinical Genitourinary Cancer
ASCO GU 2021: SURE: An Open Label, Sequential-Arm, Phase II Study of Neoadjuvant Sacituzumab Govitecan, and Sacituzumab Govitecan plus Pembro Before Radical Cystectomy, for Patients with MIBC Who Cannot Receive or Refuse
Evaluation of apremilast in chronic pruritus of unknown origin: A proof‐of‐concept, phase 2a, open‐label, single‐arm clinical trial - Clark - 2020 - Health Science Reports - Wiley Online Library
Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care - Cytotherapy
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study - The Lancet Haematology
